(Q91123974)

English

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

scientific article published on 16 January 2019

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660609%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660609%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

phase II clinical trial

1 reference

based on heuristic

inferred from title

multicenter clinical trial

1 reference

based on heuristic

inferred from title

malignant pleural mesothelioma

1 reference

based on heuristic

inferred from title

Florian Guisier

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660609%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Denis Moro-Sibilot

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660609%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

author name string

Arnaud Scherpereel

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660609%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Julien Mazieres

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660609%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Laurent Greillier

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660609%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Sylvie Lantuejoul

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660609%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Pascal Dô

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660609%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Olivier Bylicki

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660609%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Isabelle Monnet

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660609%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Romain Corre

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660609%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Clarisse Audigier-Valette

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660609%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Myriam Locatelli-Sanchez

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660609%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Olivier Molinier

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660609%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Thierry Urban

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660609%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Catherine Ligeza-Poisson

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660609%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

David Planchard

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660609%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Elodie Amour

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660609%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Franck Morin

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660609%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Gérard Zalcman

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660609%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

French Cooperative Thoracic Intergroup

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660609%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

publication date

16 January 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660609%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660609%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660609%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660609%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

239-253

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660609%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930765-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930765-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930765-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930765-4

7 January 2021

based on heuristic

inferred from DOI database lookup

British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930765-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930765-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930765-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Novel therapies for malignant pleural mesothelioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930765-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Novel insights into mesothelioma biology and implications for therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930765-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930765-4

7 January 2021

based on heuristic

inferred from DOI database lookup

CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930765-4

7 January 2021

based on heuristic

inferred from DOI database lookup

B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930765-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930765-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930765-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930765-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930765-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Modified RECIST criteria for assessment of response in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930765-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930765-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930765-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter French harmonization study for PD-L1 IHC testing in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930765-4

7 January 2021

based on heuristic

inferred from DOI database lookup

PD-L1 Testing for Immune Checkpoint Inhibitors in Mesothelioma: For Want of Anything Better?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930765-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930765-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930765-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930765-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930765-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930765-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930765-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930765-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930765-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930765-4

7 January 2021

based on heuristic

inferred from DOI database lookup

IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930765-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930765-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930765-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(18)30765-4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660609%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30660609%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q91123974&oldid=1505985717"